Patent · US Active

Treatment of glycogen synthase kinase-based disease

US8778986B1 · kind B1 · utility

6Cited by

4References

4Claims

0Family size

Assignee

University of South Florida · US

Inventors

Jun Tan · Tampa, US
Doug Shytle · Lutz, US
Kavon Rezai-Zadeh · Tampa, US

Key dates

Filing date	Jan 25, 2008
Grant date	Jul 15, 2014
Priority date	—
Expiry date	May 3, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/713
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The bioflavonoid luteolin reduces amyloid-β peptide (Aβ) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic γ-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3α activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble Aβ levels, reduced GSK-3 activity, and disrupted PS1-APP association.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.